RCS - Coiled Therapeutics - Attendance at Endless Frontier Labs 2026

Coiled TherapeuticsAnnouncement

07/05/2026 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG2936Da&default-theme=true

RNS Number : 2936D  Coiled Therapeutics PLC  07 May 2026

7 May 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

 

Attendance at Endless Frontier Labs 2026

Coiled Therapeutics to Showcase AO-252 at Prestigious Endless Frontier Labs
2026 Event

 

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company
developing precision medicines for hard-to-treat cancers, announces that it
will be featured at the prestigious Endless Frontier Labs (EFL) Frontiers 2026
event today in New York City. The Company's Chief Technology Officer, Chaemin
Lim, will present in the Oncology Diagnostics & Targeted Therapies block,
a key segment of the event's Life Sciences track.

 

Based at the NYU Stern School of Business, Endless Frontier Labs is a leading
non-profit accelerator programme for commercialising science and deep-tech
companies. Coiled Therapeutics was selected to participate in the highly
competitive nine-month EFL programme, with only 5% of applicants successfully
graduating, which is designed to help early-stage science and technology-based
companies accelerate their development.  The programme has an excellent track
record of helping to accelerate growth amongst its alumni companies.

 

The Company's admission to the programme follows the release of highly
encouraging clinical trial data for its lead asset, AO-252, a first-in-class
TACC3 inhibitor. Recent updates from the trial demonstrated an 80% Clinical
Benefit Rate in the twice daily cohort, a significant signal of efficacy in a
heavily pre-treated patient population.

 

Participation in the programme provides a significant endorsement of Coiled
Therapeutics' technology and its potential to make a major impact in the field
of oncology.   The programme offers invaluable mentorship from industry
experts, access to a network of potential investors, and business development
support from NYU Stern School of Business.

 

CEO of Coiled Therapeutics, Sridhar Vempati said: "Presenting at Endless
Frontier Labs allows us to showcase our technology and to connect with an
excellent network of investors and industry experts who recognise the
potential of our science.   We are eager to build on our recent clinical
momentum and share our vision for AO-252 to be a much-needed treatment for
patients who have exhausted all other options."

 

The Frontiers 2026 event is the culmination of the EFL programme, where the
latest cohort of companies present their innovations to an audience of
investors and industry leaders.

 

-Ends-

 

Enquiries:

 Coiled Therapeutics plc

 Sotirios Stergiopoulos (Chairman)                                          Via Burson Buchanan

 Sridhar Vempati (CEO)

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)  +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Shard Capital Partners LLP (Joint Broker)                            +44 (0)20 4530 6926

 Damon Heath

 CPS Capital Group Pty Ltd (Joint Broker)                             +61 (0)8 9223 2222

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                                   +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

 

About Endless Frontier Labs: Endless Frontier Labs is a nine-month programme
at the NYU Stern School of Business for early-stage science and
technology-based startups. The programme is designed to help early-stage
companies transform their scientific and technological ideas into commercially
scalable companies. Companies are advised by experienced entrepreneurs,
investors, and technical mentors, with a focus on achieving individualised
business goals. The Life Sciences track at EFL is specifically for companies
focused on complex problems in biology, chemistry, and related fields with
applications in therapeutics, drug discovery, diagnostics, and other
health-focused verticals.   EFL is a non-profit organisation and does not
take equity or charge fees.   https://endlessfrontierlabs.com/
(https://endlessfrontierlabs.com/)

 

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology
company focused on developing innovative precision oncology therapies. Its
lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I
clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is
actively enrolling patients to test for safety and efficacy in patients whose
cancer has progressed on other treatments.   The Company is also assessing
its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is
supported by a leadership team with a proven track record in drug development
and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small
molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3
(TACC3). TACC3 is a validated oncology target that is frequently overexpressed
in many aggressive, hard-to-treat solid tumours but is dispensable in normal
adult cells, providing a wide therapeutic window.

 

By selectively disrupting cancer-critical protein-protein interactions at the
TACC3 C-terminal domain, AO-252 induces mitotic and replication stress,
impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has
demonstrated the ability to cross the blood-brain barrier, addressing a
significant unmet medical need for the treatment of brain metastases.

 

The asset is currently in an ongoing Phase I open-label dose-escalation study
and early clinical signals have shown encouraging anti-tumour activity and a
benign safety profile, with the Company planning to initiate dose expansion
cohorts in lead indications, including prostate and ovarian cancer, during
2026.

 

For more information, please visit: www.coiledplc.com
(http://www.coiledplc.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEALSKEAEKEFA



            Copyright 2019 Regulatory News Service, all rights reserved